SCHEMBL4492860

SCHEMBL4492860

CN1CCN(C(=O)N(C)c2ccc(N)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 3/20 0.45
MAPT P10636 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MLYCD O95822 1/20 0.44
GFER P55789 2/20 0.43
ADRA2C P18825 1/20 0.43
PTK2B Q14289 1/20 0.43
ESR2 Q92731 1/20 0.43
HTR1A P08908 1/20 0.42
CSF1R P07333 1/20 0.42
HRH4 Q9H3N8 3/20 0.42
CASP6 P55212 1/20 0.41
HTT P42858 1/20 0.41
FAAH O00519 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15134846 0.85 KMT2A (0.65) GAAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL18390307 0.83 GAA (0.64) GAAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL2386026 0.83 MLYCD (0.63) GAAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL18390285 0.81 MAPT (0.55) GAAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL436539 0.80 DRD4 (0.50) GAAKMT2AALDH1A1KDM4EMAPT
SCHEMBL4486069 0.79 ALDH1A1 (0.57) GAAKMT2AMEN1ALDH1A1HRH4
SCHEMBL4481019 0.79 LMNA (0.46) GAAKMT2AALDH1A1KDM4EMAPT
SCHEMBL4495219 0.77 CYP2D6 (0.42) GAAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL26934932 0.77 FAAH (0.46) GAAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL4490990 0.76 DRD4 (0.46) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR GAA 4394/4885KMT2A 3530/4885MEN1 1288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.